Abstract
There is growing evidence that the components of the haemostatic system play a significant role in the development and progression of atherosclerosis and its complications. Lipidlowering interventions have been associated with a significant reduction of morbidity and mortality. However, the improvement in cardiovascular risk seen in several clinical trials is incompletely explained by cholesterol reduction. Therefore, the benefit from lipid lowering drugs may involve non-lipid mechanisms. These include beneficial effects on the arterial wall, improved endothelial function and a favourable influence on blood rheology and thrombogenesis. In this review, we consider the influence of lipid-lowering interventions on rheological and haemostatic parameters as well as the potential clinical relevance of these effects.
Keywords: atherothrombosis, coagulation, fibrates, fibrinogen, fibrinolysis, fish oil, rheology, haemostasis, ldlaphaeresis, lipid lowering drugs
Current Pharmaceutical Design
Title: The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Volume: 9 Issue: 29
Author(s): Haralampos J. Milionis, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: atherothrombosis, coagulation, fibrates, fibrinogen, fibrinolysis, fish oil, rheology, haemostasis, ldlaphaeresis, lipid lowering drugs
Abstract: There is growing evidence that the components of the haemostatic system play a significant role in the development and progression of atherosclerosis and its complications. Lipidlowering interventions have been associated with a significant reduction of morbidity and mortality. However, the improvement in cardiovascular risk seen in several clinical trials is incompletely explained by cholesterol reduction. Therefore, the benefit from lipid lowering drugs may involve non-lipid mechanisms. These include beneficial effects on the arterial wall, improved endothelial function and a favourable influence on blood rheology and thrombogenesis. In this review, we consider the influence of lipid-lowering interventions on rheological and haemostatic parameters as well as the potential clinical relevance of these effects.
Export Options
About this article
Cite this article as:
Milionis J. Haralampos, Elisaf S. Moses and Mikhailidis P. Dimitri, The Effects of Lipid-Regulating Therapy on Haemostatic Parameters, Current Pharmaceutical Design 2003; 9 (29) . https://dx.doi.org/10.2174/1381612033453820
DOI https://dx.doi.org/10.2174/1381612033453820 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Myocardial Protection Against Ischemia-Reperfusion Injury: Novel Approaches in Maintaining Homeostatic Stability in Blood
Recent Patents on Cardiovascular Drug Discovery The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Editorial (Epigenetics: A Paradigm Shift in Understanding Alzheimer’s Disease)
Current Alzheimer Research Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Patent Selections:
Current Regenerative Medicine (Discontinued) Cardiovascular Disease and Diabetes in South Asians: The Twin Epidemic
Current Diabetes Reviews